Tag: Heinzen

Recently promoted to full professor, Erin Heinzen, PharmD, PhD, studies the genetic causes of epilepsy and other neurodevelopmental disorders to develop new therapies for children with severe, drug-resistant seizures.

Dr. Erin Heinzen was promoted to Professor with tenure in the Division of Pharmacotherapy and Experimental Therapeutics and the Department of Genetics, effective November 14, 2025.

Department of Genetics faculty, postdocs, students and collaborators published 33 papers in September 2025.

Department of Genetics faculty, postdocs, students and collaborators published 42 papers during April 27th - May31st 2025.

Department of Genetics faculty, postdocs, students and collaborators published 18 papers during February 2nd - March 1st 2025.

Department of Genetics faculty, postdocs, students and collaborators published 18 papers during January 5th - 18th, 2025.

Department of Genetics faculty, postdocs, students and collaborators published 8 papers during August 4th - 17th 2024.

Erin Heinzen, Pharm.D., Ph.D. How seizures, epilepsy and other brain malformations develop from genetic variants is not fully understood, but a new National Institutes of Health (NIH) award will pave the way toward understanding the cause and potentially lead to new therapies.   New (non-inherited) genetic variants can arise as cells...

Department of Genetics faculty, postdocs, students and collaborators published 12 papers during June 23rd - July 6th 2024.

Erin Heinzen, PharmD, PhD (Associate Professor, Pharmacy and Genetics) was awarded a new R21 grant from NINDS for her project titled “Genotype-informed single-cell transcriptomic profiling of mosaic brain tissue”.